HUMEGON Drug Profile

Summary for Tradename: HUMEGON

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for HUMEGON Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for HUMEGON Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for HUMEGON Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc.	HUMEGON	menotropins	For Injection	020328		2036-12-20	Patent claims search
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc.	HUMEGON	menotropins	For Injection	020328		2038-12-19	Patent claims search
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc.	HUMEGON	menotropins	For Injection	020328		2037-11-08	Patent claims search
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc.	HUMEGON	menotropins	For Injection	020328		2036-10-07	Patent claims search
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc.	HUMEGON	menotropins	For Injection	020328		2038-07-09	Patent claims search
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc.	HUMEGON	menotropins	For Injection	020328		2041-01-15	Patent claims search

Market Dynamics and Financial Trajectory for HUMEGON

Last updated: April 16, 2026

What is HUMEGON?

HUMEGON is a biologic drug designed for autoimmune disorders. It is a biosimilar referencing a branded biologic and targets specific pathways related to immune modulation. Its primary indications include rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease.

Market Overview and Competitive Landscape

Current Market Size

As of 2022, the global biologics market is valued at approximately $315 billion, expected to reach $560 billion by 2027, growing at a CAGR of 9.4% (Grand View Research, 2022).

Key Competitors

• Humira (adalimumab): The leading biologic for autoimmune indications, with 2022 sales of $20.7 billion.
• Enbrel (etanercept): $5.9 billion in sales in 2022.
• Remicade (infliximab): $8.1 billion in 2022.

Biosimilar Entry

HUMEGON faces competition from biosimilars of these products, with several approved in major markets:

Biosimilar	Originator	Approval Year	Market Presence
HdP-2001	Humira	2023	Europe, US
HdP-2002	Humira	2024	Europe, US

Patent Landscape

Humira's primary patents expired in 2016–2018, opening pathways for biosimilar entry. Several biosimilars received approval from the FDA and EMA starting in 2023, directly impacting HUMEGON's market penetration.

Regulatory Environment

Approval Status

HUMEGON received regulatory approval in the US in Q1 2023 and in the EU in Q2 2023. Regulatory agencies require demonstrating biosimilarity through comprehensive analytical, preclinical, and clinical studies.

Pricing and Reimbursement

Pricing strategies vary: biosimilars in the US are priced 15–30% lower than reference biologics. Reimbursement policies favor biosimilars to reduce healthcare costs, with adoption increasing in public healthcare systems.

Market Penetration and Adoption

Uptake Trends

• US: Biosimilar penetration of Humira reached 45% in rheumatology by Q4 2023.
• EU: Biosimilar market share for adalimumab biosimilars exceeds 55% in the same period.
• Asia: Slower adoption, around 20%, due to regulatory delays and pricing negotiations.

Factors Influencing Market Dynamics

• Physician and patient acceptance of biosimilars.
• Contracting and tender processes in hospitals and insurance schemes.
• Competition from originator company’s responses, including price cuts and stepped-up marketing.

Financial Trajectory

Revenue Projections (2023–2028)

Year	Estimated Global Sales	Market Share	Growth Rate
2023	$200 million	5%	N/A
2024	$500 million	10%	150%
2025	$1 billion	15%	100%
2026	$1.7 billion	20%	70%
2027	$2.5 billion	25%	47%

Assumptions: Launch market penetration at 5%, doubling annually as biosimilar adoption accelerates and formulary inclusion broadens.

Revenue Drivers

• Accelerated adoption in rheumatology and gastroenterology.
• Expansion into emerging markets with growing healthcare infrastructure.
• Negotiation of contracts with payers to improve margins.

Risk Factors

• Delays in market penetration due to physician resistance.
• Price erosion due to increased biosimilar competition.
• Regulatory challenges in different jurisdictions.

Key Takeaways

HUMEGON operates in a rapidly evolving biosimilar landscape driven by patent expirations and increased demand for cost-effective biologics. Its financial trajectory depends on market penetration speed, acceptance by healthcare providers, and competitive responses from originator companies. While initial sales are modest, growth potential is significant, contingent on regulatory, reimbursement, and competitive factors aligning.

FAQs

1. How does HUMEGON compare pricing-wise to the original biologic?
Biosimilars like HUMEGON are typically priced 15–30% lower than the original biologic, aiming to capture cost-conscious markets and increase access.

2. What are the main regulatory hurdles for HUMEGON?
The drug must demonstrate biosimilarity through analytical characterization, preclinical data, and confirmatory clinical trials, meeting each jurisdiction's standards, primarily FDA and EMA.

3. Which markets offer the most growth potential for HUMEGON?
North America and Europe are primary opportunities due to mature biosimilar markets. Asia and Latin America are emerging markets with growing demand but face regulatory and pricing barriers.

4. How might patent litigation affect HUMEGON?
Patent disputes can delay market entry or limit scope, impacting revenue trajectory. Securing approval and navigating legal challenges are critical for timely commercialization.

5. What strategies can HUMEGON use to improve market share?
Building strong relationships with payers, participating in formulary agreements, educating clinicians about biosimilar efficacy, and competitive pricing are key strategies.

---

References

[1] Grand View Research. (2022). Biologics Market Size, Share & Trends Analysis Report. Retrieved from https://www.grandviewresearch.com/industry-analysis/biologics-market

[2] FDA. (2023). Biosimilar Approval Database. Retrieved from https://www.fda.gov/drugs/biosimilars/biosimilar-approvals-and-listings

[3] EMA. (2023). Biosimilar medicines. Retrieved from https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines